Long-Term Assets: The sum of all assets classified as non-current.
Xilio Therapeutics, Inc. (XLO) had Long-Term Assets of $9.66M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$13.69M |
|
$10.36M |
|
-- |
|
$13.69M |
|
$25.52M |
|
$-11.84M |
|
$22.20M |
|
$10.36M |
|
$10.36M |
|
$10.36M |
|
$10.36M |
|
$10.36M |
|
$10.36M |
|
$-11.84M |
|
$-11.51M |
|
8.36M |
|
8.36M |
|
$2.11 |
|
$2.11 |
|
| Balance Sheet Financials | |
$145.03M |
|
$3.89M |
|
|
Long-Term Assets |
$9.66M |
$154.69M |
|
$56.27M |
|
-- |
|
$63.14M |
|
$119.41M |
|
$35.27M |
|
$35.27M |
|
$35.27M |
|
4.53M |
|
| Cash Flow Statement Financials | |
$-4.99M |
|
$-0.52M |
|
$87.78M |
|
$57.07M |
|
$139.34M |
|
$82.27M |
|
$6.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.58 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-86.48% |
|
-86.48% |
|
-- |
|
75.70% |
|
75.70% |
|
$-5.51M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
-- |
|
2.74 |
|
32.88 |
|
29.37% |
|
29.37% |
|
6.70% |
|
29.37% |
|
$7.78 |
|
$-0.66 |
|
$-0.60 |
|